Clinical Trial Update: Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating if monosialotetrahexosylganglioside (GM1) can prevent bortezomib-induced peripheral neuropathy in patients with multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GM1 ganglioside (GM1 ganglioside)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN